Why Mylan (MYL) Hit an All-Time High Today

NEW YORK (TheStreet) -- Mylan  (MYL) soared to an all-time high of $57.06 as of 2:57 p.m. EST on Thursday after the pharmaceutical company reported fourth-quarter earnings that surpassed analysts' expectations.

The company noted earnings of 78 cents a share, excluding items, which surpassed the Capital IQ consensus estimate of 75 cents a share. Revenue rose 5.9% year over year to $1.81 billion, which equaled the consensus estimate.

Mylan also issued guidance for the fiscal year 2014 and expects earnings per share of $3.25 to $3.60 and revenue of $7.8 billion to $8.2 billion. The Capital IQ consensus estimate calls for $3.43 a share on revenue of $7.73 billion.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

MYL Chart

MYL data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

UPS's Long-Tenured Board Members Are a Red Flag for Investors

UPS's Long-Tenured Board Members Are a Red Flag for Investors

Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles

Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles

Teva Shares Fall as FDA OKs Another Generic Version of Multiple Sclerosis Drug

Teva Shares Fall as FDA OKs Another Generic Version of Multiple Sclerosis Drug

Opioid Litigants Get Boost From Senate Report

Opioid Litigants Get Boost From Senate Report

Generic Drug Makers Hurt By Latest Federal Government Budget

Generic Drug Makers Hurt By Latest Federal Government Budget